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The ‘Iressa’ Clinical Experience (ICE) meeting in Madrid provided
a unique opportunity for physicians to discuss their real-life
experiences with gefitinib (‘Iressa’, ZD1839), and has highlighted
the scope and potential of gefitinib therapy in patients with non-
small-cell lung cancer (NSCLC). The diverse patient population in
the Expanded Access Programme (EAP) included chemonaive to
eighth-line patients, patients with performance status 0–4 or
comorbidity, and elderly patients. Clinical efficacy and safety data
from these EAP patients provide further evidence that gefitinib is
active and well tolerated, supporting results from the IDEAL
(‘Iressa’ Dose Evaluation in Advanced Lung cancer) clinical trials,
which used more defined patient populations (Fukuoka et al, 2003;
Kris et al, 2003).
The diversity of case reports/series presented at the ICE meeting
has identified many potential areas of interest for physicians. For
example, preliminary data from the EAP support further
investigations regarding the efficacy of gefitinib in elderly patients
and patients with brain metastases, as well as the sequencing of
chemotherapy after gefitinib. In addition, trials in patients with
poor performance, patients who are at high risk, patients with
bronchioalveolar carcinoma and chemonaive patients are currently
ongoing or in the planning stages.
Future development of gefitinib also includes AstraZeneca-
sponsored Phase III trials in NSCLC, with two studies of gefitinib
250mgday
1 plus best supportive care (BSC) compared with
placebo plus BSC in previously treated patients. Trial 709, also
known as ISEL (‘Iressa’ Survival Evaluation in Lung cancer),
involves patients who have received platinum and docetaxel, with
the primary end point being superior survival. The second, trial
710 or IBREESE (‘Iressa’ vs BSC: a Randomised Evaluation of
Effect on pulmonary Symptom Endpoint), has pulmonary
symptom improvement rate as the primary end point. Gefitinib
250mgday
1 is being compared with docetaxel (75mgm
2 every 3
weeks) as second-line treatment in a randomised open-label trial
(721), with co-primary end points of time to progression and
survival, and additional studies will assess the potential for
gefitinib in the first-line setting. A range of other investigations
in NSCLC include cooperative group trials, evaluating gefitinib
maintenance after chemoradiation and adjuvant gefitinib after
resection, and an AstraZeneca Investigator Initiated Trial pro-
gramme.
Together with the identification of molecular and genetic
markers for sensitivity and resistance to gefitinib, these trials will
enable a more precise identification of which patients should
receive gefitinib, when they should receive it for optimum benefit
and if and how it should be sequenced with chemotherapy. Using
this rational approach, we will be able to maximise the benefit of
this novel agent for patients with NSCLC.
This meeting successfully met the objectives of bringing together
physicians from across the world to share and learn from each
other’s clinical experience of gefitinib, and has raised a number of
questions for consideration. These questions will be addressed by
an ongoing comprehensive clinical trial programme, with the
ultimate aim of improving patient care.
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